You are here: Industry Insights > AstraZeneca

News List

Tezepelumab significantly reduces exacerbations of severe asthma europeanpharmaceuticalreview
March 02, 2021
In a Phase III trial, tezepelumab was shown to meaningfully reduce annualised asthma exacerbation rates in a range of patients with severe, uncontrolled asthma.
UK to revolutionise oligonucleotide medicines manufacturing europeanpharmaceuticalreview
February 25, 2021
Collaborators on Grand Challenge 3 will utilise their combined expertise to transform the oligonucleotide supply chain.
AstraZeneca expects EUA in US for COVID-19 vaccine in April expresspharma
February 25, 2021
The company expects to be able to deliver 50 million doses of the vaccine by the end of April.
AZ withdraws Imfinzi indication in the US for advanced bladder cancer pharmatimes
February 23, 2021
AstraZeneca (AZ) has announced the voluntary withdrawal of its immunotherapy Imfinzi in its advanced bladder cancer indication in the US.
Serbia gets shipment of AstraZeneca COVID-19 vaccine made in India expresspharma
February 22, 2021
A shipment of 150,000 COVID-19 vaccines developed by AstraZeneca and Oxford University arrived at Belgrade airport on Sunday, making Serbia the first country in the Western Balkan region to receive supplies of the shot.
UK to provide COVID-19 vaccine to all adults July-end expresspharma
February 22, 2021
All adults in Britain will be offered the first shot of a COVID-19 vaccine by the end of July, Prime Minister Boris Johnson said.
IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival americanpharmaceuticalreview
February 20, 2021
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis europeanpharmaceuticalreview
February 19, 2021
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK pharmatimes
February 19, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
AstraZeneca COVID-19 Vaccine Authorized for Emergency Use by WHO americanpharmaceuticalreview
February 19, 2021
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older, including those over 65.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page